Condition: Lung Cancer · Non Small Cell Lung Cancer · Brain Metastases · Sponsor: Latin American Cooperative Oncology Group
This is a Phase II, single-arm, multicenter trial for patients with metastatic non-small cell lung cancer who have brain metastases and no known actionable mutations. Eligible patients will receive a combination of Datopotamab-deruxtecan, Carboplatin, and Pembrolizumab every three weeks for four cycles, followed by maintenance therapy with Datopotamab-deruxtecan and Pembrolizumab until disease progression or intolerable toxicity. Patients with intracranial progression but no systemic progression may receive stereotactic radiosurgery and continue treatment based on the investigator's decision.
This description comes directly from the study's public registry record.
Project Manager · +55 51 3384 5334 · lacog0823@lacog.group
Laura Voelcker · +55 51 3384 5334 · laura.voelcker@lacog.group
Always discuss trial participation with your own doctor first.
| FUNFARME - Hospital de Base de São José do Rio Preto | São José do Rio Preto, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06822543